HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $200 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Krystal Biotech (KRYS) and maintains a $200 price target.

April 22, 2024 | 5:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech's stock rating was reiterated as Buy by HC Wainwright & Co. with a maintained price target of $200.
The reiteration of a Buy rating and a high price target of $200 by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in KRYS's stock price, as it reaffirms the company's potential for growth and value creation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100